(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxy-2-(3,4,5-trihydroxybenzoyl)hexanal

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxy-2-(3,4,5-trihydroxybenzoyl)hexanal
• 化学式: C₁₃H₁₆O₁₀
• 分子量: 332.26
• InChiKey: NHTDLGVBAPMBHQ-HMHPOGMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.1
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  196
• 氢给体数：
  8
• 氢受体数：
  10

文献信息

• Compositions for treating cancer
  申请人：Fundacio Centre de Regulacio Genomica

  公开号：EP2930238A1

  公开（公告）日：2015-10-14

  The present invention relates to a Nudix5 inhibitor for use in the treatment and/or prevention of cancer in a subject and pharmaceutical compositions comprising a therapeutically effective amount of a Nudix5 inhibitor and a pharmaceutically acceptable excipient or carrier, and to a pharmaceutical composition comprising a therapeutically effective amount of a composition comprising a Nudix5 inhibitor and at least a second antitumor agent and a pharmaceutically acceptable excipient or carrier. Furthermore, the invention relates to a method for assaying the activity of Nudix5 comprising assaying the formation of ATP, and to a method for identifying a compound potentially useful for treating and/or preventing cancer comprising assaying the activity of Nudix5 in the presence of said compound.

  本发明涉及一种用于治疗和/或预防受试者癌症的Nudix5抑制剂和药物组合物，该药物组合物包含治疗有效量的Nudix5抑制剂和药学上可接受的赋形剂或载体，还涉及一种药物组合物，该药物组合物包含治疗有效量的组合物，该组合物包含Nudix5抑制剂和至少第二种抗肿瘤剂以及药学上可接受的赋形剂或载体。此外，本发明还涉及一种检测 Nudix5 活性的方法，该方法包括检测 ATP 的形成；本发明还涉及一种鉴定可能用于治疗和/或预防癌症的化合物的方法，该方法包括在所述化合物存在的情况下检测 Nudix5 的活性。
• [EN] TANNIN DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID TANNIN DERIVATIVE<br/>[FR] DÉRIVÉ DE TANNIN ET COMPOSITIONS PHARMACEUTIQUES COMPRENANT LEDIT DÉRIVÉ DE TANNIN
  申请人：SANDOZ AG

  公开号：WO2014090832A1

  公开（公告）日：2014-06-19

  The invention concerns a tannin derivative, in particular tannin derivative having antibiotic activity, obtained by covalent coupling of at least one organic acid with at least one tannin, the covalent coupling is formed as an ester or ether bond, and wherein the acid residue provides at least one functional group for covalently coupling at least one pharmaceutically active ingredient, a pharmaceutical composition comprising or consisting of said tannin derivative and a method for producing said tannin derivatives.